In order to complete existing projects, Alembic Pharmaceuticals has earmarked a capital expenditure of Rs 720 crore for FY19. The company had spent about Rs 600 crore of capex in the last fiscal year.
The pharma firm has filed 12 ANDAs (abbreviated new drug applications) during the March quarter, taking the total filings in FY18 to 26.
The company has six formulation and three API manufacturing facilities. It manufactures general oral solids in Panelav near Vadodara, Gujarat, and is in the process of putting up oncology oral solids and oncology injectable facilities at the same location.
